How to manage heart failure in a patient with drug-induced exfoliative dermatitis, specifically DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome?

Managing Heart Failure in Drug-Induced Exfoliative Dermatitis (DRESS Syndrome)

Immediately discontinue the suspected causative drug and initiate systemic corticosteroids (IV methylprednisolone 1-2 mg/kg/day), while carefully monitoring cardiac function with echocardiography and cardiac biomarkers, as cardiac involvement in DRESS occurs in 4-21% of cases and carries significant mortality risk. 1, 2

Immediate Management Priorities

Drug Discontinuation and Cardiac Assessment

• Stop all suspected causative medications immediately as this is the single most critical intervention for DRESS syndrome 1, 3
• Perform urgent echocardiography to assess for myocarditis, particularly if hemodynamic instability, hypotension, or cardiac symptoms are present 2, 4
• Obtain cardiac biomarkers (troponin, BNT-proBNP) at presentation and serially monitor if cardiac involvement is suspected 2
• Assess NYHA functional class and left ventricular ejection fraction to guide heart failure management 5, 6

Systemic Corticosteroid Therapy

• Initiate IV methylprednisolone 1-2 mg/kg/day immediately upon diagnosis of DRESS syndrome, regardless of cardiac involvement 1, 3
• Unlike Stevens-Johnson syndrome, corticosteroids are NOT contraindicated in DRESS and are the cornerstone of treatment 3, 7
• Plan for a minimum 4-week taper to prevent relapse, as DRESS involves T-cell immune-directed toxicity with long-lasting memory responses 1, 3
• Start proton pump inhibitor for gastrointestinal prophylaxis during corticosteroid therapy 8

Heart Failure Management in DRESS Context

Standard Heart Failure Therapy

• Diuretics and salt restriction are indicated for fluid retention, using loop diuretics (furosemide 20-40 mg once or twice daily, titrated to effect) 6
• ACE inhibitors should be used for heart failure with reduced ejection fraction, unless contraindicated 6
• Beta-blockers (bisoprolol, carvedilol, or sustained-release metoprolol succinate) are recommended for stable patients with reduced LVEF, but exercise caution during acute DRESS-associated myocarditis 6

Critical Contraindications and Cautions

• Avoid TNF antagonist therapy entirely if severe (NYHA class III-IV) heart failure is present, as trials showed excess mortality with infliximab 5
• Withdraw calcium channel blockers with negative inotropic effects in patients with ejection fraction <40% 6
• Discontinue NSAIDs as they adversely affect heart failure outcomes and may have been the causative agent for DRESS 6

Monitoring and Escalation

Intensive Monitoring Requirements

• Admit to intensive care unit or burn unit for severe DRESS cases with cardiac involvement 3, 7
• Monitor for cardiac arrhythmias, as DRESS-associated myocarditis can cause life-threatening dysrhythmias 2, 4
• Serial echocardiography to assess ventricular function, as cardiac symptoms range from asymptomatic to cardiogenic shock 2
• Complete blood count with differential to track eosinophilia (>700/μL or >10%) 3, 9
• Comprehensive metabolic panel for liver (ALT >2x upper limit) and kidney function (creatinine >1.5x baseline) 3, 9

Refractory Cases

• Consider IVIG (1-2 g/kg total dose) or cyclosporine for steroid-unresponsive DRESS 3
• Plasmapheresis may be beneficial in fulminant myocarditis cases 10
• Mechanical circulatory support (ECMO, intra-aortic balloon pump, ventricular assist devices) should be considered for refractory cardiogenic shock 2, 4, 10
• Inotropic support (dopamine, dobutamine, milrinone) may be necessary for severe left ventricular dysfunction 10

Critical Pitfalls to Avoid

Common Errors

• Do not delay corticosteroid initiation while awaiting definitive diagnosis, as early treatment reduces mortality from cardiac involvement 4
• Do not perform premature steroid taper (minimum 4 weeks required), as relapse occurs in 12% of cases 11, 1
• Do not rechallenge with the suspected drug, as DRESS involves severe T-cell-mediated delayed reactions with long-lasting memory 3
• Do not perform patch testing or delayed intradermal testing until at least 6 months after resolution and at least 1 month off systemic corticosteroids (>10 mg prednisone equivalent) 11, 1, 3

Diagnostic Vigilance

• Maintain high suspicion for cardiac involvement even without overt symptoms, as myocarditis can be subclinical initially 2
• Recognize that DRESS has a 2-6 week latency period after drug exposure, distinguishing it from immediate reactions 1, 3, 12
• Be aware that dilated cardiomyopathy may develop as a late sequela, requiring long-term echocardiographic follow-up 10

Multidisciplinary Consultation

• Immediate dermatology consultation for all suspected DRESS cases 1, 3
• Cardiology consultation if any cardiac symptoms, biomarker elevation, or echocardiographic abnormalities are present 2, 4
• Nephrology involvement for renal dysfunction (creatinine >1.5x baseline) 3
• Infectious disease consultation for infection control in ICU setting 7

Prognosis and Long-Term Considerations

• Mortality from DRESS syndrome is approximately 10%, primarily from visceral organ compromise including cardiac involvement 7, 2
• Complete recovery is possible with early drug withdrawal and appropriate corticosteroid therapy 4
• Long-term cardiac monitoring is essential, as dilated cardiomyopathy may develop months after acute illness 10
• Elevated serum creatinine and ferritin at presentation predict fatal outcomes 3